Cartesian Therapeutics, Inc. (RNAC) 追踪市盈率为负值 -1.2, 表示公司目前在过去十二个月 (TTM) 基础上处于亏损状态。 追踪盈利收益率为 -82.38%.
本页证实的标准:
SharesGrow 综合评分： 56/100 其中 3/7 项标准通过。
| Year | P/E (TTM) | PEG 比率 | P/B 比率 | P/S 比率 | 股息收益率 |
|---|---|---|---|---|---|
| 2016 | -4.1 | -0.11 | 2.73 | 18.55 | - |
| 2017 | -2.6 | 0.35 | 3.22 | 806.64 | - |
| 2018 | -0.8 | 0.09 | -9.16 | 54.96 | - |
| 2019 | -1.6 | 0.03 | 10.76 | 13.53 | - |
| 2020 | -3.7 | 0.08 | -14.19 | 15.40 | - |
| 2021 | -12.1 | 0.18 | 13.79 | 3.65 | - |
| 2022 | 3.9 | -0.02 | 1.45 | 1.23 | - |
| 2023 | -0.5 | 0.00 | -0.23 | 3.91 | - |
| 2024 | -6.0 | 0.06 | -68.21 | 11.92 | - |
| 2025 | -1.4 | -0.02 | -1.48 | 66.95 | - |
| Year | EPS（稀释） | 营收 | 净利润 | 净利润率 |
|---|---|---|---|---|
| 2016 | $-103.52 | $8.08M | $-36.21M | -448% |
| 2017 | $-95.94 | $207K | $-65.32M | -31556% |
| 2018 | $-87.55 | $903K | $-65.34M | -7235.4% |
| 2019 | $-36.46 | $6.68M | $-55.35M | -829% |
| 2020 | $-20.42 | $16.6M | $-68.88M | -415% |
| 2021 | $-6.74 | $85.08M | $-25.69M | -30.2% |
| 2022 | $3.00 | $110.78M | $35.38M | 31.9% |
| 2023 | $-49.76 | $26M | $-219.71M | -844.9% |
| 2024 | $-0.50 | $38.91M | $-77.42M | -199% |
| 2025 | $-5.02 | $2.8M | $-130.3M | -4658.6% |
| Year | EPS（平均） | EPS 范围 | 营收（平均） | 营收范围 | 分析师人数 |
|---|---|---|---|---|---|
| 2026 | $-3.29 | $-3.99 – $-2.53 | $716.17K | $404.61K – $971.07K | 5 |
| 2027 | $-3.58 | $-4.62 – $-1.88 | $716.17K | $632.89K – $799.44K | 3 |
| 2028 | $-3.40 | $-5.00 – $-2.06 | $24.22M | $17.92M – $29.66M | 5 |
| 2029 | $-2.69 | $-3.48 – $-1.78 | $90.6M | $67.03M – $110.94M | 1 |
| 2030 | $-0.97 | $-1.25 – $-0.64 | $218.2M | $161.42M – $267.19M | 1 |
